The Journal of Neuroscience, February 28, 2007, 27(9):2377-2386; doi:10.1523/JNEUROSCI.2949-06.2007
Previous Article | Next Article 
Neurobiology of Disease
High-Frequency Stimulation of the Subthalamic Nucleus Potentiates L-DOPA-Induced Neurochemical Changes in the Striatum in a Rat Model of Parkinson's Disease
Abid Oueslati,1
Véronique Sgambato-Faure,2,3
Christophe Melon,1
Philippe Kachidian,1
Paolo Gubellini,1
Mohammed Amri,4
Lydia Kerkerian-Le Goff,1 and
Pascal Salin1
1Developmental Biology Institute of Marseille Luminy, Unité Mixte de Recherche 6216, Centre National de la Recherche ScientifiqueUniversité de la Méditerranée, 13402 Marseille cedex 20, France, 2Neurosciences Précliniques, Institut National de la Santé et de la Recherche Médicale U318, 38043 Grenoble cedex, France, 3Dynamique des Réseaux Neuronaux, Institut National de la Santé et de la Recherche U704Université Joseph Fourier, 38041 Grenoble Cedex 9, France, and 4Laboratoire de Physiologie de la Nutrition, Faculté des Sciences de Tunis, 2092 El Manar, Tunis, Tunisia
Correspondence should be addressed to Pascal Salin, Team "Cellular Interactions, Neurodegeneration and Neuroplasticity," Developmental Biology Institute of Marseille Luminy, Unité Mixte de Recherche 6216, Centre National de la Recherche ScientifiqueUniversité de la Méditerranée, 31 chemin Joseph Aiguier, 13402 Marseille cedex 20, France. Email: salin{at}ibdml.univ-mrs.fr
This study examined the cellular changes produced in the striatum by chronic L-DOPA treatment and prolonged subthalamic nucleus high-frequency stimulation (STNHFS) applied separately, successively, or in association, in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease (PD). Only animals showing severe L-DOPA-induced dyskinesias (LIDs) were included, and STNHFS was applied for 5 d at an intensity efficient for alleviating akinesia without inducing dyskinesias. L-DOPA treatment alone induced FosB/
FosB immunoreactivity, exacerbated the postlesional increase in preproenkephalin, reversed the decrease in preprotachykinin, and markedly increased mRNA levels of preprodynorphin and of the glial glutamate transporter GLT1, which were respectively decreased and unaffected by the dopamine lesion. STNHFS did not affect per se the postlesion changes in any of these markers. However, when applied in association with L-DOPA treatment, it potentiated the positive modulation exerted by L-DOPA on all of the markers examined and tended to exacerbate LIDs. After 5 d of L-DOPA withdrawal, the only persisting drug-induced responses were an elevation in preprodynorphin mRNA levels and in the number of FosB/
FosB-immunoreactive neurons. Selective additional increases in these two markers were measured when STNHFS was applied subsequently to L-DOPA treatment. These data provide the first evidence that STNHFS exacerbates the responsiveness of striatal cells to L-DOPA medication and suggest that STNHFS acts specifically through an L-DOPA-modulated signal transduction pathway associated with LIDs in the striatum. They point to striatal cells as a primary site for the complex interactions between these two therapeutic approaches in PD and argue against a direct anti-dyskinetic action of STNHFS.
Key words: deep brain stimulation; L-DOPA; dyskinesias; neuropeptides; FosB; GLT1; motor cortex
Received July 12, 2006;
revised Jan. 25, 2007;
accepted Jan. 27, 2007.
Correspondence should be addressed to Pascal Salin, Team "Cellular Interactions, Neurodegeneration and Neuroplasticity," Developmental Biology Institute of Marseille Luminy, Unité Mixte de Recherche 6216, Centre National de la Recherche ScientifiqueUniversité de la Méditerranée, 31 chemin Joseph Aiguier, 13402 Marseille cedex 20, France. Email: salin{at}ibdml.univ-mrs.fr